Pharmaron
Company: Pharmaron
Description: Pharmaron, trading under the stock codes 300759SZ and 3759HK, stands as a leading service provider within the life sciences industry. Established in 2004, Pharmaron has made significant investments in its personnel and facilities, resulting in the creation of a comprehensive suite of research, development, and manufacturing services. These capabilities span the entire drug discovery process, including preclinical and clinical development, and cater to a wide array of therapeutic modalities such as small molecules, biologics, and advanced cell and gene therapy (CGT) products.
With a workforce exceeding 20,000 employees, Pharmaron operates across multiple regions, including China, the United States, and the United Kingdom. The company has demonstrated a strong track record in providing research and development solutions to its partners throughout North America, Europe, Japan, and China.
Pharmaron offers an extensive range of services designed to support its clients through various stages of drug development. These services encompass synthetic medicinal and analytical chemistry, biology services, drug metabolism and pharmacokinetics (DMPK), pharmacology services, drug safety assessments, radiochemistry, and isotopically labeled metabolism services, as well as chemical and pharmaceutical development. In addition, Pharmaron provides clinical development services that aid in the progression of drug candidates through clinical trials.
The company’s capabilities also include specialized areas such as library synthesis, bioorganic chemistry, discovery process chemistry, radiolabeled chemical synthesis, and cheminformatics. Moreover, Pharmaron is equipped to handle in vitro and in vivo biology studies, animal disease models, pharmacokinetics (PK), and pharmacodynamics (PD), as well as quality assurance and regulatory affairs.
Pharmaron actively addresses various aspects of drug creation and assessment, including biopharmaceuticals and the manufacturing of active pharmaceutical ingredients (APIs). The organization excels in material science, formulation development, drug product manufacturing, toxicology, safety pharmacology, genetic toxicology, and pathology.
With a commitment to advancing scientific knowledge and meeting industry demands, Pharmaron continues to be a trusted partner in the life sciences sector, providing vital support throughout the drug development lifecycle. For more information, Pharmaron can be explored at www.pharmaron.com.
Industry: Pharmaceutical Manufacturing
Domain: http://www.pharmaron.com/
Location: Beijing
Address: 6 Taihe Road, BDA, Beijing, 100176, CN
Size: 10,001+ employees
Direct Contacts
Name: Xiaoqian Chen
Title: Vice President of Operation
Email: Direct Email
Company: Bayland Capital 康君资本
Industry: Pharmaceutical Manufacturing
Location: Shanghai, China
Name: Maggie Wang
Title: VP
Email: Direct Email
Company: Bayland Capital 康君资本
Industry: Pharmaceutical Manufacturing
Location: Shanghai, China